ArticleMolecular therapy. Nucleic acids2024
MHGTMDA: Molecular heterogeneous graph transformer based on biological entity graph for miRNA-disease associations prediction.
Article in Molecular therapy. Nucleic acids, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Protein Sequence Analysis landscape: A Systematic Review of Task Types, Databases, Datasets, Word Embeddings Methods, and Language Models.Database : the journal of biological databases and curation · 2025Pooled it
- Transitioning from wet lab to artificial intelligence: a systematic review of AI predictors in CRISPR.Journal of translational medicine · 2025Pooled it
- CoupleMDA: Metapath-Induced Structural-Semantic Coupling Network for miRNA-Disease Association Prediction.International journal of molecular sciences · 2025Article
- GONNMDA: A Ordered Message Passing GNN Approach for miRNA-Disease Association Prediction.Genes · 2025Article
- Review
- DNA sequence analysis landscape: a comprehensive review of DNA sequence analysis task types, databases, datasets, word embedding methods, and language models.Frontiers in medicine · 2025Review
- DGNMDA: Dual Heterogeneous Graph Neural Network Encoder for miRNA-Disease Association Prediction.Bioengineering (Basel, Switzerland) · 2024Article
- A multichannel graph neural network based on multisimilarity modality hypergraph contrastive learning for predicting unknown types of cancer biomarkers.Briefings in bioinformatics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) play a crucial role in the prevention, prognosis, diagnosis, and treatment of complex diseases. Existing computational methods primarily focus on biologically relevant molecules directly associated with miRNA or disease, overlooking the fact that the human body is a highly complex system where miRNA or disease may indirectly correlate with various types of biomolecules. To address this, we propose a novel prediction model named MHGTMDA (miRNA and disease association prediction using heterogeneous graph transformer based on molecular heterogeneous graph). MHGTMDA integrates biological entity relationships of eight biomolecules, constructing a relatively comprehensive heterogeneous biological entity graph. MHGTMDA serves as a powerful molecular heterogeneity map transformer, capturing structural elements and properties of miRNAs and diseases, revealing potential associations. In a 5-fold cross-validation study, MHGTMDA achieved an area under the receiver operating characteristic curve of 0.9569, surpassing state-of-the-art methods by at least 3%. Feature ablation experiments suggest that considering features among multiple biomolecules is more effective in uncovering miRNA-disease correlations. Furthermore, we conducted differential expression analyses on breast cancer and lung cancer, using MHGTMDA to further validate differentially expressed miRNAs. The results demonstrate MHGTMDA's capability to identify novel MDAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.